ArticleJournal of the American Academy of Dermatology2022
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Article in Journal of the American Academy of Dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Immune-checkpoint inhibitor-induced bullous pemphigoid in patients with metastatic renal cell carcinoma: two case reports and systematic review of the literature.Acta oncologica (Stockholm, Sweden) · 2026Pooled it
- Real-World Cutaneous Immune-Related Adverse Events of Immunotherapy in Melanoma: A Systematic Review and Meta-Analysis.Dermatology and therapy · 2026Pooled it
- Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review.Frontiers in neurology · 2024Pooled it
- Best evidence for managing cutaneous immune-related adverse events in cancer: A summary from Chinese and English literature.Asia-Pacific journal of oncology nursing · 2026Review
- Poliosis predicts durable response to immune-checkpoint blockade in metastatic melanoma: a multicenter cohort study.Journal for immunotherapy of cancer · 2026Article
- Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- [Erythroderma: etiology, diagnosis, and management-an overview].Dermatologie (Heidelberg, Germany) · 2026Review
- Enfortumab vedotin-induced cutaneous toxicities and their association with survival in urothelial carcinoma.medRxiv : the preprint server for health sciences · 2026Article
- Successful Treatment of Immune-Related Grover's Disease with Isotretinoin.Dermatology practical & conceptual · 2026Article
- Erythema Multiforme Associated With Pembrolizumab Treatment for Recurrent Urothelial Carcinoma: A Case Report.Cureus · 2026Article
- Risk factors for cutaneous immune-related adverse events: a systematic scoping review.Frontiers in immunology · 2026Article
- Article
- [Management of immune-related cutaneous toxicities].Magyar onkologia · 2025Review
- The Current State and Future Prospects for Artificial Intelligence in Dermatology.Dermatologic clinics · 2025Review
- Neuromuscular complications associated with cancer immunotherapy.Journal of the National Cancer Center · 2025Review
- Dermatologic toxicities related to cancer immunotherapy.Toxicology reports · 2025Article
- Higher incidence of dermatological immune-related adverse events in cancer patients treated with immune checkpoint inhibitors vs. other treatments: a TriNetX research network study.Archives of dermatological research · 2025Article
- Research in practice: Immune checkpoint inhibitor related autoimmune bullous dermatosis.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Review
- NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors.JAAD international · 2025Article
- Immune Checkpoint Inhibitor-Induced Vitiligo-Like Depigmentation.JAMA dermatology · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundA variety of dermatoses have been reported in the growing number of patients treated with immune-checkpoint inhibitors (ICIs), but the current understanding of cutaneous immune-related adverse events (irAEs) is limited.
objectiveTo determine the cumulative incidence, distribution, and risk factors of cutaneous irAEs after ICI initiation.
methodsThis was a retrospective cohort study of patients in a national insurance claims database including cancer patients treated with ICIs and matched controls.
resultsThe study included 8637 ICI patients and 8637 matched controls. The overall incidence of cutaneous irAEs was 25.1%, with a median onset time of 113 days. The ICI group had a significantly higher incidence of pruritus, mucositis, erythroderma, maculopapular eruption, vitiligo, lichen planus, bullous pemphigoid, Grover disease, rash, other nonspecific eruptions, and drug eruption or other nonspecific drug reaction. Patients with melanoma and renal cell carcinoma and those receiving combination therapy were at a higher risk of cutaneous irAEs. LIMITATIONS: Retrospective design without access to patient chart data.
conclusionsThis study identifies cutaneous irAEs in a real-world clinical setting and highlights patient groups that are particularly at risk. The results can aid dermatologists at the bedside in the diagnosis of cutaneous irAEs and in formulating management recommendations to referring oncologists regarding the continuation of ICI therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.